Rituximab in the treatment of non-Hodgkin’s lymphoma

نویسندگان

  • Beate Hauptrock
  • Georg Hess
چکیده

INTRODUCTION The use of rituximab has led to significant improvements in the outcome of both aggressive and indolent Non-Hodgkin's lymphoma (NHL). It is the first targeted therapy to be developed for the treatment of lymphoma which has been widely adopted. AREAS COVERED This paper discusses the use of rituximab in NHL, mainly concentrating on diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL), with a brief discussion about use in other types of NHL including mantle cell lymphoma (MCL). The use of rituximab in chronic lymphocytic leukemia (CLL) has been recently published in this journal by Robak (Robak T. Rituximab for chronic lymphocytic Leukemia. Expert Opin Biol. Ther. 2012;12(4):503-15). Non hematological indications for rituximab are also not discussed. A Pubmed search was conducted using key words of rituximab, DLBCL, FL, MCL, Burkitt's lymphoma and MALToma. Papers shortlisted for review included randomized control trials and scientific papers discussing CD20. EXPERT OPINION In conclusion this paper has critically evaluated the use of rituximab in the treatment mainly of DLBCL, FL and MCL both at diagnosis and relapsed disease, and briefly discuses its use in other subtypes of lymphoma. Rituximab has significantly improved the outcome of patients with B cell NHL, in particular those with DLBCL and FL. Patients usually tolerate the treatment well, and studies have shown it to be a cost effective treatment.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Physicochemical evaluation of lyophilized formulation of p-SCN-Bn-DOTA-and p-SCN-Bn-DTPA-rituximab for NHL radioimmunotherapy

Radioimmunotherapy (RIT) of Non-Hodgkin’s lymphoma (NHL) is said to be more advantageous compared to unlabelled therapeutic antibodies. To this date, radiolabelled murine anti-CD20 mAbs, Zevalin® and Bexxar® have been approved for imaging and therapy. A preparation containing rituximab, chimeric mAb radioimmunoconjugate suitable for Lu-177 labeling, could provide better imaging and therapeutic ...

متن کامل

Development of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

متن کامل

Development of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

متن کامل

Extranodal Non-Hodgkin’s Lymphoma of the Oral Cavity Presenting as Gingival Swelling: A Case Report

Non-Hodgkin’s lymphoma is a heterogeneous malignancy originating from proliferation of lymphoid cells or their precursors. , we report a case of a 6-year-old Iranian male child admitted at the Department of Oral Medicine, School of Dentistry, Mashhad, Iran, in March 2019. The case was complaining about gingival swellings worsening for one month. Clinical and pathologic examination, comple...

متن کامل

Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era.

Non-Hodgkin’s lymphoma is the fifth most common and sixth most fatal cancer in the United States and has increased significantly in incidence over the past 30 years. The National Cancer Institute estimates that 60,000 new cases of nonHodgkin’s lymphoma will be diagnosed in the United States this year; the most common of which is diffuse large B-cell nonHodgkin’s lymphoma (1). Diffuse large B-ce...

متن کامل

Rituximab for post-transplant lymphoproliferative disease _PTLD.pub

Rituximab is a monocloncal antibody that binds specifically to CD20, an antigen expressed on the surface of mature and immature B lymphocytes. The binding of rituximab to CD20 results in cell lysis via the recruitment of immune effector functions; it has also been demonstrated to induce cell death via apoptosis. Rituximab (Mabthera®) is licensed in the UK for the treatment of Non-Hodgkin’s lymp...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 2  شماره 

صفحات  -

تاریخ انتشار 2008